Souhaitez-vous accéder aux communiqués récents ?

Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary...

, May 14, 2026 (GLOBE NEWSWIRE) -- AUSTIN, Texas – May 14, 2026 – EDAP TMS S.A. (Nasdaq: EDAP) today announced that it has entered into a letter of intent with Telix Pharmaceuticals Limited...

MELBOURNE, Australia , May 13, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for...

AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and...

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Antonio F. Santidrian, PhD, Chief Scientific Officer and Head of Technical Operations for Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or...

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor...

Interim results from SIDNEY Phase 2 trial show EO2463 rapidly induced extensive in vivo expansion of B cell target-specific CD8 T-cellsCorrelation established between EO2463-induced and B cell...

Strengthening of CPTx executive team with appointment of Edward Rebar, PhD, as Chief Scientific Officer. David Maier is appointed Chief Business Officer.

NAPERVILLE, Ill., May 09, 2026 (GLOBE NEWSWIRE) -- A Pint for Kim, the national grassroots movement founded in 2020 in honor of Kimberly Sandford, once again made history—breaking its own record for...

White Oak, Md., May 08, 2026 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive...